Introduction
Cell and gene therapies are defined as medical treatments that use living cells or genetic material to treat disease, including approaches such as CAR-T therapy, CRISPR based editing, and stem cell therapy. These therapies depend on biological materials from donors, which are defined as cells or tissues collected from humans.
A donor ecosystem is the full system responsible for collecting, testing, processing, and distributing donor material for medical and clinical use. The article describes current donor ecosystems as fragmented, meaning these steps are not unified under a single system and instead operate across different regions and regulatory frameworks.
Methods / Approach
The article is an industry and regulatory analysis of the biomedical supply chain, which is the full process that moves donor material from collection to final therapeutic manufacturing. The analysis compares regulatory systems such as those governed by the FDA with international regulatory frameworks in other regions.
It also uses real world examples from cell and gene therapy programs, including CAR-T therapy, stem cell therapy, and CRISPR based treatments, to evaluate how donor systems function in practice. Industry reports and manufacturing data are used to identify inefficiencies and bottlenecks in the system.
Analysis
The donor supply chain is defined as the system that includes donor recruitment, biological collection, testing, processing, and manufacturing. In practice, these stages are often separated across different locations, a condition defined as supply chain fragmentation. This fragmentation increases cost, complexity, and delivery time.
Two major therapy types are used to structure the analysis:
• Autologous therapy, defined as treatment using a patient’s own cells
• Allogeneic therapy, defined as treatment using donor cells that can be used across multiple patients
Allogeneic therapies depend on donor scalability, which is defined as the ability of a system to consistently produce enough high quality donor material for large patient populations.
Regulatory systems are formal rules that control how biological materials are tested, approved, and used. Differences between these systems across countries make global standardization difficult.
The United States is described as having stronger infrastructure, defined as the integrated systems for donor collection, testing, and distribution. This is supported by:
large and genetically diverse donor pools
standardized regulatory oversight
established collection and testing networks
Results / Finding
The article finds that donor systems function as core infrastructure in cell and gene therapy manufacturing, meaning they are essential systems required for production and delivery of treatments. Without scalable donor networks, large scale therapy deployment is limited.
A clear shift is identified toward allogeneic therapies, which are standardized donor based treatments that can be manufactured in advance and used across multiple patients. This increases dependence on efficient donor ecosystems.
The United States is a leading hub due to its regulatory consistency, infrastructure strength, and donor diversity, which enable more scalable and reliable production systems altogether.
Key system constraints identified include:
supply chain fragmentation across regions and institutions
regulatory differences between countries
limited donor recruitment and processing scalability
Conclusion
The article concludes that donor ecosystems are a foundational part of modern cell and gene therapy development. A donor ecosystem is defined as the system that enables sourcing, processing, and distribution of biological materials for therapy production.
As allogeneic therapies expand, the demand for standardized and scalable donor infrastructure increases. The ability of a system to manage donor material efficiently directly determines how widely advanced therapies can be used in the future.
